Harry Haber - Concepedia

Concepedia

Author

Harry Haber

Eli Lilly (United States)

Also Known As

H. Haber, HARRY HABER, Harry E Haber, Harry E. Haber, Harry Haber

32

Publications

2.8K

Citations

18

H-Index

42

Concepts

All Affiliations

Eli Lilly (United States)University of Michigan University of Florida University of British Columbia Dalhousie University

HH

About

Harry Haber is an author at Eli Lilly (United States) specializing in medicine, cardiovascular disease, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	910
2	Public Health	3	3	98
3	Social Sciences	1	1	18
4	Diabetes	1	1	24
5	Epidemiology	1	1	21

Harry Haber

×

23

Publications

2.8K

Citations

18

H-Index

	Year	Citations
Angiotensin-Converting Enzyme Inhibition With Quinapril Improves Endothelial Vasomotor Dysfunction in Patients With Coronary Artery Disease G.B. John Mancini, Gregory C. Henry, Carlos Macaya, Circulation	1996	1.1K
Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor J.W. Nawrocki, Stuart Weiss, Michael H. Davidson, Arteriosclerosis Thrombosis and Vascular Biology	1995	484
Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) Todd J. Anderson, Eleanor Elstein, Harry Haber, Journal of the American College of Cardiology HypertensionCardiovascular DiseaseMedicineBanff StudyPhysiology	2000	362
The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ace inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function Bertram Pitt, Blair J. O’Neill, Robert Feldman, The American Journal of Cardiology Heart FailureCardiovascular DiseaseIschemic Heart DiseaseAtherosclerosisCardiovascular Pharmacology	2001	228
Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks Michaëla Diamant, Luc Van Gaal, Stephen Stranks, Diabetes Care	2012	96
Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in <scp>A</scp>sian patients with type 2 diabetes mellitus Linong Ji, Yukiko Onishi, Chul Woo Ahn, Journal of Diabetes Investigation	2012	77
Evaluation of methods for achieving stable INR in healthy subjects during a multiple-dose warfarin study Jill C. Chappell, Gemma L. Dickinson, Malcolm I. Mitchell, European Journal of Clinical Pharmacology ThrombosisMultiple-dose Warfarin StudyHealthy SubjectsCardiovascular DiseaseMedicine	2011	62
Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects Jutta Keller, Michael Trautmann, Harry Haber, Regulatory Peptides Healthy SubjectsBiliary TractGastrointestinal PharmacologyPharmacologyGastroenterology	2012	60
Effects of Quinapril on Coronary Blood Flow in Coronary Artery Disease Patients With Endothelial Dysfunction Jay D. Schlaifer, Thomas J. Wargovich, Blair J. O’Neill, The American Journal of Cardiology Cardiovascular DiseaseMedicineEndothelial DysfunctionCoronary Blood FlowVascular Biology	1997	56
Effects of angiotensin-converting enzyme inhibition on transient ischemia Carl J. Pepine, Jean‐Lucien Rouleau, Karen Annis, Journal of the American College of Cardiology HypertensionCardiovascular DiseaseMedicineCardiovascular PharmacologyVascular Biology	2003	48

Page 1